Thyroid Fine-needle Aspiration Cytology: Performance Data of Neoplastic and Malignant Cases As Identified from 1558 Responses in the ASCP Non-GYN Assessment Program Thyroid Fine-needle Performance Data
Overview
Authors
Affiliations
Background: Fine-needle aspiration of the thyroid is a common procedure, with an established role in reducing unnecessary thyroid surgery and identifying neoplasms and malignancies.
Methods: The study evaluated 1558 responses in the American Society for Clinical Pathology (ASCP) Non-GYN Assessment program of aspirates of thyroid neoplasms and malignancies and placed them into the following groups: group A (target or correct interpretation), group B (incorrect interpretation as a benign thyroid nodule), group C (incorrect interpretation malignant aspirate as thyroid neoplasm), and group D (malignant diagnosis with incorrect interpretation). In clinical practice, responses in groups A, C, and D would lead to surgical excision, whereas responses in group B would not.
Results: Of a total of 1558 responses, 78.5% of the responses were in group A, 8.5% in group B, 3.75% in group C, and 9.25% in group D. By individual diagnosis, the group rates were 86.5%, 0%, 11%, and 2.5% for anaplastic thyroid carcinoma; 83%, 5.5%, 4.25%, and 7.25% for papillary thyroid carcinoma; 79%, 7%, 6%, and 8% for medullary thyroid carcinoma; 83.5% 6.75%, 0%, and 9.75% for Hürthle cell neoplasm; and 61%, 22%, 0%, and 17% for follicular neoplasm in groups A, B, C, and D respectively.
Conclusions: Fine-needle aspiration was effective in diagnosing thyroid neoplasms and malignancies and in separating thyroid nodules into surgical and nonsurgical categories. Data from a large group of cytology professionals showed good performance; however, there is room for improvement, especially in making specific diagnoses. In particular, follicular neoplasm and follicular variant of papillary thyroid carcinoma were challenging diagnoses for participants.
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses.
Matrone A, De Napoli L, Torregrossa L, Aghababyan A, Papini P, Ambrosini C Front Oncol. 2022; 12:854755.
PMID: 35463338 PMC: 9022105. DOI: 10.3389/fonc.2022.854755.
Bible K, Kebebew E, Brierley J, Brito J, Cabanillas M, Clark Jr T Thyroid. 2021; 31(3):337-386.
PMID: 33728999 PMC: 8349723. DOI: 10.1089/thy.2020.0944.
Cervical ultrasound assessment of thyroid nodules at risk of malignancy: single-center experience.
Neagoe O, Ionica M, Mazilu O G Chir. 2017; 38(5):233-238.
PMID: 29280703 PMC: 5761636. DOI: 10.11138/gchir/2017.38.5.233.
Janczak D, Pawlowski W, Dorobisz T, Janczak D, Dorobisz K, Lesniak M Onco Targets Ther. 2016; 9:5819-5823.
PMID: 27703381 PMC: 5036625. DOI: 10.2147/OTT.S111275.
Kim T, Jeong D, Hahn S, Shin J, Oh Y, Ki C Cancer Med. 2016; 5(5):769-77.
PMID: 26775803 PMC: 4864806. DOI: 10.1002/cam4.636.